How can I determine if esketamine (Spravato) is worsening a patient’s condition?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Monitoring for Esketamine Treatment Failure or Worsening

Monitor for worsening depressive symptoms, emergence or intensification of suicidal ideation, and new-onset dissociative or psychotic symptoms during the first 4 weeks of treatment—if these occur despite esketamine therapy, consider discontinuation as the medication may be causing paradoxical worsening rather than improvement. 1

Key Clinical Indicators of Treatment Failure or Worsening

Primary Warning Signs (Weeks 1-4)

Depressive Symptom Deterioration:

  • Use standardized scales (Montgomery-Asberg Depression Rating Scale or Clinical Global Impression scales) to objectively track symptom trajectory 1
  • Look for lack of improvement or actual worsening of core depressive symptoms (anhedonia, hopelessness, psychomotor changes) within the first 4 weeks
  • The 2022 VA/DoD guidelines emphasize that therapeutic benefit should be evaluated at the end of the 4-week induction phase 2

Suicidal Ideation Changes:

  • Critical caveat: While esketamine is approved for acute suicidal ideation in MDD, its effectiveness in preventing suicide or reducing suicidal behavior has NOT been established 2, 3
  • Monitor closely for new-onset or worsening suicidal thoughts, particularly in the first weeks of treatment 3
  • The FDA boxed warning specifically highlights increased risk of suicidal thoughts and behaviors, requiring close monitoring 3

Paradoxical Reactions:

  • Case reports document patients who initially responded to esketamine but then experienced rapid deterioration with worsening depression and suicidal ideation 1
  • Upon discontinuation, these patients improved and showed reduction in suicide ideation 1
  • This phenomenon may be difficult to identify in highly treatment-resistant patients, but awareness is critical 1

Adverse Events Indicating Poor Tolerance

Acute Session-Related Events (Monitor for 2 hours post-dose):

  • Severe dissociation (most common adverse event, RR 5.90-10.65 depending on dose) 4, 5, 6
  • Significant blood pressure elevation (>40 mmHg systolic or >25 mmHg diastolic occurs in 3-19% of patients) 3, 4
  • Severe sedation or unresponsiveness to stimuli 4, 7
  • Hypertensive crisis symptoms: chest pain, shortness of breath, sudden severe headache, visual disturbances, seizures 3

Dose-Dependent Adverse Events: High-dose esketamine (≥56 mg nasal or 0.40 mg/kg IV) carries significantly higher risk than low-dose (≤28 mg or 0.20 mg/kg):

  • Nausea: RR 3.72 vs 1.69 5
  • Dissociation: RR 10.65 vs 3.27 5
  • These events increase discontinuation risk by 2.22-fold 5

Emerging Safety Signals: Real-world pharmacovigilance has identified concerning new signals:

  • Homicidal ideation (ROR 5.30) 7
  • Substance use disorder/abuse (ROR 6.12) 4, 7
  • Interstitial cystitis 4
  • Drug diversion 4
  • Abnormal behavior and aggression (particularly in women) 7

High-Risk Patient Populations

Patients with Comorbid Substance Use Disorders: Esketamine is disproportionately prescribed to patients with comorbid SUD, and these patients experience significantly worse outcomes 8:

  • Higher risk of self-harm (HR 2.99)
  • Higher risk of suicide attempt (HR 2.13)
  • Increased emergency visits (HR 1.78)
  • Increased hospitalization (HR 1.70)
  • Increased mortality (HR 1.12)

This represents a prescribing bias that requires enhanced monitoring and specialized care 8

Structured Monitoring Algorithm

Week 1 Assessment:

  • Pre-dose blood pressure screening (delay if >140/90 mmHg) 3
  • Post-dose monitoring for 2 hours minimum 3
  • Blood pressure measurement at 40 minutes post-dose and as needed until normalized 3
  • Document frequency and severity of dissociation, sedation, nausea, vertigo, dizziness 9
  • Key principle: Events occurring twice in week 1 are more likely to recur than those occurring once 9

Weeks 2-4 (Induction Phase):

  • Continue structured adverse event monitoring
  • Serial depression rating scales (weekly MADRS or equivalent)
  • Specific assessment for suicidal ideation at each visit
  • Monitor for cognitive impairment (attention, judgment, reaction speed) 3
  • Watch for paradoxical worsening despite initial response 1

Week 4 Decision Point:

If no therapeutic benefit is evident by week 4, discontinue esketamine 2. The evidence does not support continuing beyond 4 weeks without demonstrated improvement.

Beyond Week 4 (If Continuing):

  • Most adverse events decrease in frequency with ongoing treatment 9
  • However, long-term cognitive and memory impairment have been reported with repeated ketamine misuse 3
  • The 2025 VA/DoD guidelines note insufficient evidence regarding esketamine's effect on suicide attempts or suicide risk 10

Critical Clinical Pitfalls

  1. Mistaking lack of efficacy for treatment resistance: If depressive symptoms fail to improve or worsen by week 4, this is treatment failure, not an indication to continue 2

  2. Overlooking paradoxical reactions: Initial response followed by deterioration may represent a paradoxical depressive response requiring discontinuation 1

  3. Inadequate blood pressure monitoring: Substantial BP increases can occur after any dose, even if previous doses were well-tolerated 3

  4. Underestimating risk in SUD patients: These patients require specialized monitoring given their significantly worse outcomes 8

  5. Assuming suicidal ideation improvement: The effectiveness of esketamine in preventing suicide has not been established, despite its indication for acute suicidal ideation 2, 3

Drug Interactions Requiring Enhanced Monitoring

  • Psychostimulants: Closely monitor blood pressure with concomitant use 3
  • MAOIs: Closely monitor blood pressure with concomitant use 3
  • Venlafaxine: Potential additive interaction signal for dizziness 7
  • Bupropion: Potential additive interaction signal for agitation 7
  • Risperidone: Potential additive interaction signal for vertigo 7

Sex-Specific Considerations

Women show longer time to adverse event onset compared to men (p=0.003) and different adverse event profiles 7:

  • More likely in women: oxygen saturation decreased, abnormal behavior, unresponsiveness to stimuli, aggression
  • More likely in men: vision blurred, bradycardia

References

Related Questions

Can anxiety be a sign of manic activation caused by Spravato (esketamine) nasal spray?
Does esketamine (Spravato) cause anxiety when discontinued?
For esketamine (Spravato), what factors determine whether to start with a 84 mg dose versus a 56 mg dose?
In a patient with a history of substance‑use disorder who is receiving Spravato (esketamine) and has improved depression but new‑onset anxiety, how should the management be approached?
How should I manage anxiety that began three days after receiving Spravato (esketamine) treatment?
When do diastolic murmurs characteristically begin and end in relation to the heart sounds?
In an 8‑month pregnant woman with a 15‑day cough, rhinorrhea, sneezing and right infra‑scapular crepitations, can amoxicillin‑clavulanic acid, pantoprazole, cetirizine and paracetamol be prescribed, and what duration is appropriate for each?
What are the complications of Neisseria meningitidis infection?
What is Waterhouse‑Friderichsen syndrome?
What is the typical clinical presentation of idiopathic intracranial hypertension in a young to middle‑aged overweight woman?
What is the recommended dosing of potassium phosphate (K‑Phos) for treating hypophosphatemia in adults and children, including intravenous and oral regimens and adjustments for renal impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.